<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01518231</url>
  </required_header>
  <id_info>
    <org_study_id>Zhejiang Hospital</org_study_id>
    <nct_id>NCT01518231</nct_id>
  </id_info>
  <brief_title>Autologous Hematopoietic Stem Cell Transplantation in Ischemic Stroke</brief_title>
  <acronym>AHSCTIS</acronym>
  <official_title>Phase 1 Study of Autologous Peripheral Hematopoietic Stem Cell Transplantation in Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhejiang Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of autologous peripheral
      hematopoietic stem cell transplantation in ischemic stroke.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Stroke is among the main causes of mortality and disability of elderly population which still
      lack of efficient therapy. Stem sell transplantation provides a functional improvement after
      cerebral ischemia in rat models. Our study will recruit 40 ischemic stroke patients which
      will be divided into 2 groups (20 patients each): treatment group and control group. The
      former will be implanted with peripheral blood stem cell through anterior cerebral artery or
      middle cerebral artery (determined by the section of infarction) and receive convention
      stroke therapy. The latter only receive convention stroke therapy. The investigators expect
      that transplantation of the peripheral hematopoietic stem cell is safe and efficient to
      neurological recovery.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in NIH-stroke scale (NIHSS) at 12 months</measure>
    <time_frame>1,3,6,12 months after cell transplantation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Barthel index</measure>
    <time_frame>1,3,6,12 months after cell transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>perfusion magnetic resonance imaging scan</measure>
    <time_frame>1,3,6,12 months after cell transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale(mRS)</measure>
    <time_frame>3,6,12 months after cell transplantation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>cell transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study group will not only be implanted with autologous hematopoietic stem cells, but also receive drug therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Convention therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The control group just receive drug therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous hematopoiesis stem cell transplantation</intervention_name>
    <description>Every participant will be transplanted with about 4 million autologous peripheral blood stem cell(CD34+) through cerebral artery.</description>
    <arm_group_label>cell transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>aspirin 100mg,qd,po(patients with no fibrillation atrial)</description>
    <arm_group_label>cell transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>warfarin 2~6mg,qd,po(patients with fibrillation atrial);</description>
    <arm_group_label>cell transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>atorvastatin 20mg,qd,po</description>
    <arm_group_label>cell transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edaravone</intervention_name>
    <description>edaravone 30mg,bid,ivgtt.</description>
    <arm_group_label>cell transplantation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>aspirin 100mg,qd,po(patients with no fibrillation atrial)</description>
    <arm_group_label>Convention therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>warfarin 2~6mg,qd,po(patients with fibrillation atrial)</description>
    <arm_group_label>Convention therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>atorvastatin 20mg,qd,po</description>
    <arm_group_label>Convention therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edaravone</intervention_name>
    <description>edaravone 30mg,bid,ivgtt</description>
    <arm_group_label>Convention therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  aged 40~70

          -  no consciousness disorders

          -  internal carotid artery territory infarction

          -  stroke happened &lt; 1 year

          -  with stable hemiplegia, but remain dependent in daily life

          -  SSS(Scandinavian Stroke Scale) &lt; 40

        Exclusion Criteria:

          -  pregnant women

          -  can't tolerate the test because of other disease, such as heart failure, liver
             failure, renal failure, abnormal blood coagulation, AIDS, combine other tumor or
             special condition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yaguo Li, master</last_name>
    <role>Study Director</role>
    <affiliation>Zhejiang Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yumiao Zhou, master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yaguo Li, master</last_name>
    <phone>0086-0571-87987373</phone>
    <phone_ext>5103</phone_ext>
    <email>tjqlyg@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yumiao Zhou, master</last_name>
    <phone>0086-0571-87987373</phone>
    <phone_ext>5094</phone_ext>
    <email>zlf859@yahoo.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Yaguo Li</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yumiao Zhou, master</last_name>
      <phone>0086-0571-87987373</phone>
      <phone_ext>5094</phone_ext>
      <email>zlf859@yahoo.com.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2012</study_first_submitted>
  <study_first_submitted_qc>January 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2012</study_first_posted>
  <last_update_submitted>January 24, 2012</last_update_submitted>
  <last_update_submitted_qc>January 24, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang Hospital</investigator_affiliation>
    <investigator_full_name>Yaguo Li</investigator_full_name>
    <investigator_title>Yaguo Li</investigator_title>
  </responsible_party>
  <keyword>stroke</keyword>
  <keyword>hematopoietic stem cell transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Antipyrine</mesh_term>
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Phenylmethylpyrazolone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

